Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	9.29B +0.8%
Revenue (ttm)	15.96B -1.5%
Net Income	309.80M -53.4%
EPS	0.12 -54.1%
Shares Out	2.52B
PE Ratio	30.84
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,110,898
Average Volume	218,321,378
Open	3.650
Previous Close	3.690
Day's Range	3.580 - 3.690
52-Week Range	3.200 - 4.880
Beta	0.19
RSI	45.91
Earnings Date	Apr 23, 2026

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2025, SHA:600664's revenue was 15.96 billion, a decrease of -1.31% compared to the previous year's 16.18 billion. Earnings were 361.60 million, a decrease of -42.50%.